Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

被引：0
|
作者：
S Redaelli
F Boschelli
P Perini
A Pirola
M Viltadi
C Gambacorti-Passerini
机构：
[1] University of Milano-Bicocca,Department of Clinical Medicine and Prevention
[2] S.Gerardo Hospital,undefined
[3] Center for Integrative Biology and Therapeutics,undefined
[4] Pfizer Research,undefined
[5] Pearl River,undefined
[6] NY,undefined
[7] USA. E-mail carlo.gambacorti@unimib.it,undefined
来源：
Leukemia | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1223 / 1227
页数：4
相关论文
共 50 条
  • [31] Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
    Nam, Hyun-Jin
    Im, Seock-Ah
    Oh, Do-Youn
    Elvin, Paul
    Kim, Hwang-Phill
    Yoon, Young-Kwang
    Min, Ahrum
    Song, Sang-Hyun
    Han, Sae-Won
    Kim, Tae-You
    Bang, Yung-Jue
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (01) : 16 - 26
  • [32] Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer.
    Campone, M.
    Bondarenko, I
    Brincat, S.
    Epstein, R. J.
    Munster, P. N.
    Dubois, E.
    Martin, E. C.
    Turnbull, K.
    Zacharchuk, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S268 - S268
  • [33] Binding mode of the tyrosine kinase inhibitor bosutinib (SKI-606) to Abl kinase
    Soverini, S.
    Tasco, G.
    Grafone, T.
    Colarossi, S.
    Gnani, A.
    Baccarani, M.
    Casadio, R.
    Martinelli, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
    Campone, M.
    Bondarenko, I.
    Brincat, S.
    Hotko, Y.
    Munster, P. N.
    Chmielowska, E.
    Fumoleau, P.
    Ward, R.
    Bardy-Bouxin, N.
    Leip, E.
    Turnbull, K.
    Zacharchuk, C.
    Epstein, R. J.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 610 - 617
  • [35] Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
    Uz, B.
    Bektas, O.
    Eliacik, E.
    Goker, H.
    Erbilgin, Y.
    Sayitoglu, M.
    Sayinalp, N.
    Aksu, S.
    Buyukasik, Y.
    Ozcebe, O.
    Haznedaroglu, I. C.
    CASE REPORTS IN HEMATOLOGY, 2011, 2011
  • [36] Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
    Zook, Phillip
    Pathak, Harsh B.
    Belinsky, Martin G.
    Gersz, Lawrence
    Devarajan, Karthik
    Zhou, Yan
    Godwin, Andrew K.
    von Mehren, Margaret
    Rink, Lori
    CLINICAL CANCER RESEARCH, 2017, 23 (01) : 171 - 180
  • [37] Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Katagiri, Seiichiro
    Tanaka, Yuko
    Ohyashiki, Kazuma
    BLOOD, 2012, 120 (21)
  • [38] The SRC/ABL inhibitor BMS-354825 overcomes resistance to imatinib mesylate in chronic myelogenous leukemia cells through multiple mechanisms.
    Donato, NJ
    Wu, J
    Kong, LY
    Lee, F
    Talpaz, M
    BLOOD, 2004, 104 (11) : 549A - 549A
  • [39] Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors
    Messersmith, W. A.
    Krishnamurthi, S.
    Hewes, B. A.
    Zacharchuk, C. M.
    Abbas, R.
    Martins, P.
    Dowling, E.
    Volkert, A.
    Martin, E.
    Daud, A. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] EVALUATION OF THE EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS ( PK) OF BOSUTINIB ( SKI-606), A DUAL INHIBITOR OF SRC AND ABL TYROSINE KINASES, WHEN ADMINISTERED CONCOMITANTLY TO HEALTHY SUBJECTS.
    Abbas, R.
    Boni, J.
    Hug, B.
    Leister, C.
    Burns, J.
    Sonnichsen, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S87 - S87
12345